Another study also failed to show improvement in objective response rate or progression-free survival with combination therapy of selumetinib and erlotinib over monotherapy in KRAS mutant and KRAS wild-type advanced lung cancer [17]. The gene discussed is KRAS; the disease is lung carcinoma.